Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717473 | PMC |
| http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
No evidence for increased habitual or decreased goal-directed action control after acute stress.
PLoS One
September 2025
Department of Psychology, Technische Universität Dresden, Dresden, Germany.
Previous studies suggested that acute stress can impair flexible goal-directed action control in favor of habitual action control. In addition, there is evidence that acute stress differentially affects the processing of rewards and punishments. Therefore, we aimed at investigating whether acute stress affects the balance between goal-directed and habitual behavior not only for behavior aiming at reward but also for behavior motivated by avoiding punishments.
View Article and Find Full Text PDFCryptosporidium Diarrhea in a Patient With Class IV Lupus Nephritis on Cyclophosphamide: An Underreported Case.
Cureus
August 2025
Medicine and Surgery, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Vijayawada, IND.
is a protozoan parasite that typically causes self-limited diarrhea in healthy individuals but can result in prolonged, severe illness in those who are immunocompromised. While this infection is well recognized in HIV-positive patients, it is less frequently reported in individuals with lupus nephritis on immunosuppressive therapy. We report the case of a 27-year-old man with biopsy-confirmed class IV lupus nephritis who was receiving cyclophosphamide and corticosteroids.
View Article and Find Full Text PDFEffect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
Lancet Rheumatol
September 2025
National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Electronic address:
Background: The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.
Methods: We did a double-blind, randomised, placebo-controlled, parallel-group, single-centre study in adults with treatment-naïve active psoriatic arthritis.
The changing landscape of primary autoimmune neuropathies.
Nat Rev Neurol
September 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau (IR SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.
Autoimmune neuropathies, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are rare, disabling disorders. Diagnosis, follow-up and treatment of autoimmune neuropathies rely almost exclusively on clinical parameters, and the available therapies, such as intravenous immunoglobulins and corticosteroids, date from >30 years ago. The lack of therapeutic progress in autoimmune neuropathies has resulted from a combination of limited understanding of their pathophysiology, disease heterogeneity and challenges in trial design.
View Article and Find Full Text PDFTHE DOSE-RESPONSE OF INHALED CORTICOSTEROIDS IN COMBINATION ICS/LABA MAINTENANCE THERAPY FOR ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Chest
September 2025
Medical Research Institute of New Zealand, Wellington, New Zealand, ; Victoria University of Wellington, Wellington, New Zealand.
Background: High doses of maintenance inhaled corticosteroids (ICS) in asthma may achieve only modest additional clinical benefit beyond low-to-medium doses and are associated with an increased risk of adverse systemic effects. The ICS dose-response relationship when administered as maintenance combination ICS/long-acting beta-agonist (LABA) therapy is uncertain.
Research Question: What is the ICS dose-response of maintenance ICS/LABA therapy?
Methods: A systematic review of randomized controlled trials (RCTs) allocating participants to >1 ICS dose category, per Global Initiative for Asthma categorization, administered in combination ICS/LABA inhalers was conducted.